An update from Imugene Limited ( (AU:IMU) ) is now available.
Imugene Limited has appointed Darren Keamy as its new Chief Financial Officer and Company Secretary. Keamy, with over 25 years of experience in corporate finance within the biopharmaceutical industry, previously played a crucial role in the growth of Clinuvel Pharmaceuticals. His expertise in financial strategy and international expansion is expected to support Imugene’s strategic growth and the advancement of its immuno-oncology pipeline.
More about Imugene Limited
Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative therapies that harness the immune system to treat cancer. The company is engaged in advancing its pipeline of immunotherapies to improve cancer treatment outcomes.
YTD Price Performance: 12.50%
Average Trading Volume: 133,181
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $171.9M
See more insights into IMU stock on TipRanks’ Stock Analysis page.